Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 13 October 2017, 09:48 HKT/SGT
Share:
    

Source: Eisai
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan

TOKYO, Oct 13, 2017 - (JCN Newswire) - Eisai Co., Ltd., Toyama Chemical Co., Ltd. of the Fujifilm Group and Taisho Pharmaceutical Co., Ltd. today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd.

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.
I
guratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying AntiRheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram Tablets 25 mg and KOLBET Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.
About anti-rheumatic agent KOLBET Tablets 25 mg (generic name: iguratimod)

Indications and Usage: Rheumatoid arthritis
Dosage and Administration: The recommended adult dosage of iguratimod is one 25 mg tablet taken orally once daily after breakfast for at least four weeks, after which the dosage should be increased to one 25 mg tablet taken twice daily (after breakfast and after dinner).

About Toyama Chemical Co., Ltd.

Toyama Chemical Co., Ltd. is a core company of the Fujifilm Group responsible for the "treatment" area of Fujifilm's healthcare business. It works to develop innovative new medicines in its primary focus areas of infectious diseases, neurological diseases, and inflammatory diseases. By producting stable new drug candidates of an international standard and combining them with Fujifilm's technology, it aims to further strengthen its R&D and production capibilities. Toyama Chemical specializes in pharmaceutical research and development, and strives to contribute to the further development of global health care through new drug development. For more information about Toyama Chemical Co., Ltd., please visit www.toyama-chemical.co.jp/en/.

About Taisho Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Co., Ltd. conducts research, development, manufacturing and marketing of over-the-counter (OTC) medicine, special health foods, food products, medical products, and hygiene products (self-medication business) as well as research, development, manufacturing and marketing of ethical pharmaceuticals (prescription pharmaceutical business). While leading the market with top-share OTC medicines including Lipovitan D, Pavulon, and RiUP, Taisho Pharmaceutical is enhancing its development capabilities for new prescription medicines. While exploiting the synergy between these two businesses, it seeks to contribute to the realization of a healthier and more prosperous life that everyone desires. For more information about Taisho Pharmaceutical Co., Ltd., please visit www.taisho.co.jp/en/.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: